Funding for this research was provided by:
Joint Funds for the Innovation of Science and Technology (2019Y9037)
Natural Science Foundation of Fujian Province (2020J05071)
Fujian Province Health Middle-aged and Young backbone personnel training Project (2020GGB010)
the Startup Fund for scientific research, Fujian Medical University (2019QH1192)
National Clinical Key Specialty Construction Program and Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy (2020Y2012)
Received: 18 January 2022
Accepted: 3 May 2022
First Online: 15 May 2022
: The study protocol was designed in accordance with the guidelines outlined in the Declaration of Helsinki. All information was retrospectively extracted in the context of compliance with the relevant regulations and protection of patients’ privacy. All the participants signed an informed consent form. This study was approved by the Ethical Review Committee of Fujian Cancer Hospital. All animal studies were performed in accordance with the ARRIVE and IACUC guidelines. All methods were performed in accordance with relevant guidelines and regulations.
: Not applicable.
: The authors declare that they have no competing interests.